Bonnefoi H, Lerebours F, Pulido M, Arnedos M, et al. Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial. Lancet Oncol 2025 Feb 17:S1470-2045(24)00737.
PMID: 39978376